BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5367-5384
DOI: 10.1021/acs.molpharmaceut.6c00398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 07.10.2026. Verfasst von Jiale Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou310053, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Berberine, B7-H1 Antigen, Anthraquinones. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Natural Science Foundation of Hangzhou City.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) therapy is limited by the poor efficacy of anti-programmed death-ligand 1 (aPD-L1) monotherapy, with dysregulated lipid metabolism in the tumor microenvironment (TME) driving immunosuppression. Herein, a nanoemulsion co-loaded with berberine (BBR) and rhein (RHE) (BBR-RHE-NE), two lipid-modulating bioactives from Dahuang Huanglian Xiexin Decoction, was fabricated to remodel the immunosuppressive TME and boost aPD-L1 efficacy in TNBC. BBR-RHE-NE was characterized with a small droplet size (185.8 ± 0.44 nm), narrow polydispersity (PDI: 0.12 ± 0.02), and good stability. In orthotopic 4T1Fluc TNBC mouse models, BBR-RHE-NE monotherapy inhibited tumor growth, and its combination with aPD-L1 exerted robust synergistic anti-tumor activity. Flow cytometry revealed that BBR-RHE-NE, as a monotherapy or in combination with aPD-L1, enhanced effector immune cell infiltration and reduced immunosuppressive subsets in both tumor tissues and spleens. Lipidomic analysis, Oil Red O staining, and enzymatic assays confirmed BBR-RHE-NE reduced intratumoral lipid droplet accumulation and downregulated intratumoral triacylglycerols and fatty acids (FAs) levels both in vitro and in vivo. Mechanistically, RNA sequencing and functional validation experiments demonstrated that BBR-RHE-NE potentiated aPD-L1 efficacy via PPARγ/FABP4-mediated lipid metabolic remodeling, a process that promoted dendritic cell maturation and was attenuated by the PPARγ agonist GW1929. Moreover, BBR-RHE-NE exhibited excellent biocompatibility with no detectable organ toxicity. Collectively, these findings demonstrate that BBR-RHE-NE effectively remodels the immunosuppressive TME through lipid metabolic reprogramming, offering a promising nanomedicine-based combinatorial strategy to enhance aPD-L1 immunotherapy for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou310053, China.
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang310016, China.
- Lishui Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Lishui323000, China.
ORCID-Profile: Mancang Gu, Chaofeng Mu, Yang Xiong
Förderung
- Natural Science Foundation of Zhejiang Province
- Natural Science Foundation of Hangzhou City
Zitieren
APA
Wei, J., Qian, K., Shi, J., Chen, K., Zhang, H., Gu, M., Mu, C., Chen, L., & Xiong, Y. (2026). BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer. Molecular Pharmaceutics, 23(11), 5367-5384. https://doi.org/10.1021/acs.molpharmaceut.6c00398
Vancouver
Wei J, Qian K, Shi J, Chen K, Zhang H, Gu M, et al. BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2026;23(11):5367-5384. doi:10.1021/acs.molpharmaceut.6c00398
BibTeX
@article{Wei2026,
author = {Wei, Jiale and Qian, Ke and Shi, Jingbin and Chen, Kexin and Zhang, Hongyan and Gu, Mancang and Mu, Chaofeng and Chen, Lifei and Xiong, Yang},
title = {BBR-RHE Co-Loaded Nanoemulsion Potentiates Anti-PD-L1 Efficacy via Lipid Metabolic Reprogramming in Triple-Negative Breast Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5367--5384},
doi = {10.1021/acs.molpharmaceut.6c00398}
}
EUVIMED